Hepatitis vaccines are essential tools in preventing viral infections that target the liver, specifically Hepatitis A and Hepatitis B. The Hepatitis A vaccine is vital for safeguarding against contamination-related infections, commonly transmitted through contaminated food or water. It is particularly recommended for travelers to regions with a higher prevalence of Hepatitis A. The Hepatitis B vaccine is a key component in preventing chronic Hepatitis B infections, which can lead to severe liver diseases, including cirrhosis and liver cancer. Administered as part of routine childhood immunization schedules, it is also recommended for adults, especially those at an increased risk of exposure. Combined vaccines, such as the Hepatitis A and B combination, provide comprehensive protection against both viruses. Beyond individual protection, widespread vaccination efforts contribute significantly to public health by reducing the overall burden of Hepatitis-related diseases globally. Continuous research and development efforts aim to expand vaccine coverage, addressing additional Hepatitis strains and reinforcing the commitment to preventing and controlling Hepatitis infections on a global scale. Regular vaccination campaigns and healthcare initiatives remain critical in promoting broad immunization against Hepatitis.
Title : A universal AI design framework and brokerage platform for democratised manufacturing of mRNA therapeutics
Duccio Medini, BioForge, United States
Title : Personalized and Precision Medicine (PPM) via biodesign-driven translational applications and upgraded business modeling to secure the human biosafety: The next-step vaccinomics of the future
Sergey V Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Development of VSV-vector based vaccine against H5N1 avian influenza by targeting both H5N1 hemagglutinin and matrix protein 2
Zhujun Ao, University of Manitoba, Canada
Title : A novel responsive microneedle platform for reliable drug and vaccine delivery
Huanhuan Li, Queen’s University Belfast, United Kingdom
Title : Emerging nanovaccine strategies for enhanced immune targeting and vaccine performance
Aysel Sadayli, V.Y. Axundov Scientific-Research Institute of Medical Prophylaxis, Azerbaijan
Title : The promise of nanotechnology in Personalized & Precision Medicine: Nano-driven precision vaccinomics of the future
Sergey V Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Reaching zero-dose children through adaptive immunization strategies in security-compromised areas of Zamfara State, Nigeria
Attahir Abubakar, Ahmadu Bello University, Nigeria
Title : Comparative efficacy of different H9N2 avian influenza virus inactivated vaccines using some commercially available adjuvants for superior control in broilers
Ayman H M El Deeb, Cairo University, Egypt
Title : Structure-based design and development of next-generation Respiratory Syncytial Virus (RSV) vaccine
Lei Chen, Yikang Biotech Suzhou Co., Ltd, China
Title : Unmasking urban immunization inequities: A cross-sectional LQAS analysis of zero-dose drivers in slum and non-slum settings of Uttar Pradesh, India
Ashish Kumar Maurya, John Snow India, India